Insider Selling: SiBone (NASDAQ:SIBN) Insider Sells $60,321.24 in Stock

Posted by Geri Gentry on Oct 9th, 2026

SiBone (NASDAQ:SIBN – Get Free Report) insider Anshul Maheshwari sold 3,318 shares of the company’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $18.18, for a total value of $60,321.24. Following the completion of the transaction, the insider directly owned 219,966 shares in the company, valued at approximately $3,998,981.88. The trade was a 1.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anshul Maheshwari also recently made the following trade(s):

On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The stock was sold at an average price of $19.50, for a total value of $33,754.50.
On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The shares were sold at an average price of $20.11, for a total value of $233,999.96.
On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $224,784.56.
On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The shares were sold at an average price of $19.55, for a total value of $112,353.85.
On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $18.65, for a total value of $87,002.25.

SiBone Price Performance

Shares of SIBN opened at $18.86 on Friday. The firm has a market cap of $836.42 million, a PE ratio of -55.47 and a beta of 0.66. The firm’s 50 day moving average price is $18.80 and its 200 day moving average price is $16.28. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. SiBone has a twelve month low of $11.48 and a twelve month high of $21.89.

SiBone (NASDAQ:SIBN – Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The company had revenue of $56.01 million during the quarter, compared to the consensus estimate of $55.34 million. As a group, research analysts expect that SiBone will post -0.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Truist Financial reiterated a “buy” rating and set a $23.00 price target (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. UBS Group increased their price objective on SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, TD Cowen raised their price objective on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $24.17.

View Our Latest Stock Report on SiBone

Institutional Trading of SiBone

A number of institutional investors and hedge funds have recently modified their holdings of the company. First Light Asset Management LLC grew its stake in shares of SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock valued at $132,649,000 after purchasing an additional 2,774,795 shares during the last quarter. Granahan Investment Management LLC boosted its stake in SiBone by 97.6% during the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after acquiring an additional 858,942 shares during the last quarter. Paradigm Capital Management Inc. NY grew its holdings in shares of SiBone by 113.3% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock valued at $14,228,000 after buying an additional 598,300 shares during the period. Renaissance Technologies LLC raised its position in shares of SiBone by 101.6% during the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock worth $5,969,000 after purchasing an additional 238,219 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in SiBone by 41.8% in the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock valued at $7,816,000 after buying an additional 182,465 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

SiBone Company Profile

(Get Free Report)

SI-BONE, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of disorders affecting the sacroiliac joint, which connects the spine to the pelvis. The company’s technology is intended to support minimally invasive procedures for patients with sacroiliac joint dysfunction and related conditions.

Its product portfolio includes the iFuse Implant System, a family of triangular titanium implants designed to stabilize and fuse the sacroiliac joint.